STOCK TITAN

Annexon (ANNX) director buys 4,115 shares under Rule 10b5-1 plan

Filing Impact
(Low)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

Annexon, Inc. director reports open-market stock purchase under a Rule 10b5-1 plan. On 12/01/2025, the reporting person bought 4,115 shares of Annexon common stock in a transaction coded as a purchase. The weighted average purchase price was $4.47 per share, with individual trades executed between $4.43 and $4.50.

After this transaction, the director beneficially owned 50,290 shares held directly. The filing notes that the trades were made pursuant to the director’s Rule 10b5-1 trading plan adopted on March 17, 2025, and the director has agreed to provide detailed trade information within the reported price range upon request.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Carson William H.

(Last) (First) (Middle)
C/O ANNEXON, INC.
1400 SIERRA POINT PKWY, BLDG C, STE 200

(Street)
BRISBANE CA 94005

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Annexon, Inc. [ ANNX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
12/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/01/2025 P(1) 4,115 A $4.47(2) 50,290 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted March 17, 2025.
2. This transaction was executed in multiple trades in prices ranging from $4.43 to $4.50, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.
/s/ Jennifer Lew, Attorney-in-Fact 12/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Annexon (ANNX) report in this Form 4?

A director of Annexon, Inc. reported buying 4,115 shares of common stock in an open-market purchase on 12/01/2025.

What price did the Annexon (ANNX) director pay for the purchased shares?

The shares were bought at a weighted average price of $4.47 per share, with trades executed between $4.43 and $4.50.

How many Annexon (ANNX) shares does the director own after this transaction?

Following the reported purchase, the director beneficially owned 50,290 shares of Annexon common stock held directly.

Was the Annexon (ANNX) insider trade made under a Rule 10b5-1 trading plan?

Yes. The filing states the transactions were made under the director’s Rule 10b5-1 trading plan adopted on March 17, 2025.

Can investors get more detailed pricing information about the Annexon (ANNX) insider trades?

Yes. The director has undertaken to provide, upon request, full information on the number of shares purchased at each price within the $4.43–$4.50 range.

What is the relationship of the reporting person to Annexon (ANNX)?

The reporting person is identified as a director of Annexon, Inc. and filed the Form 4 as one reporting person.
Annexon, Inc.

NASDAQ:ANNX

ANNX Rankings

ANNX Latest News

ANNX Latest SEC Filings

ANNX Stock Data

770.62M
134.89M
0.42%
100.05%
9.22%
Biotechnology
Pharmaceutical Preparations
Link
United States
BRISBANE